Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ophthalmology
  Free Subscription

Articles published in
Lancet
    September 2025
  1. KIRTANE AJ, Stone GW
    Orbital atherectomy for stent implantation: the ECLIPSE trial - Authors' reply.
    Lancet. 2025;406:1221-1222.
    >> Share

  2. KHIALANI B, Frazzetto M, Touma G, Cortese B, et al
    Orbital atherectomy for stent implantation: the ECLIPSE trial.
    Lancet. 2025;406:1220.
    >> Share

  3. PROTTY MB, Hussain H, Hailan A, Choudhury A, et al
    Orbital atherectomy for stent implantation: the ECLIPSE trial.
    Lancet. 2025;406:1220-1221.
    >> Share

    May 2025
  4. HABTAMU E, Harding-Esch EM, Greenland K, Wamyil-Mshelia T, et al
    Trachoma.
    Lancet. 2025;405:1865-1878.
    >> Share

    March 2025
  5. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    >> Share

  6. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    >> Share

    February 2025
  7. MICHAELIDES M, Laich Y, Wong SC, Oluonye N, et al
    Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
    Lancet. 2025;405:648-657.
    >> Share

    January 2025
  8. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
    Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Lancet. 2025;405:303-313.
    >> Share

  9. FOELL D, Heiligenhaus A
    Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
    Lancet. 2025;405:274-276.
    >> Share

    November 2024
  10. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    >> Share

  11. HIRAMI Y, Mandai M
    Opening the door to widespread iPSC-derived regenerative therapy for corneal epithelial opacity.
    Lancet. 2024 Nov 7:S0140-6736(24)01965-2. doi: 10.1016/S0140-6736(24)01965.
    >> Share

    September 2024
  12. YANG P, Pardon LP, Ho AC, Lauer AK, et al
    Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
    Lancet. 2024;404:962-970.
    >> Share

  13. MACLAREN RE
    Gene therapy in the early stages of retinal degeneration.
    Lancet. 2024;404:911-913.
    >> Share

    August 2024
  14. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    >> Share

  15. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    >> Share

  16. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
    Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Lancet. 2024;404:540-553.
    >> Share

  17. COLAFRANCESCO S, Priori R
    Sjogren's disease: a new era for clinical trials?
    Lancet. 2024;404:498-499.
    >> Share

    July 2024
  18. PATEL JN, Miller NR
    Non-arteritic anterior ischaemic optic neuropathy causes sudden-onset painless loss of vision.
    Lancet. 2024;404:67.
    >> Share

    June 2024
  19. YING GS, VanderBeek BL
    Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Lancet. 2024 Jun 11:S0140-6736(24)00915-2. doi: 10.1016/S0140-6736(24)00915.
    >> Share

  20. JACKSON TL, Desai R, Wafa HA, Wang Y, et al
    Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
    Lancet. 2024 Jun 11:S0140-6736(24)00687-1. doi: 10.1016/S0140-6736(24)00687.
    >> Share

    May 2024
  21. PROUDLOCK FA, Hisaund M, Maconachie G, Papageorgiou E, et al
    Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
    Lancet. 2024;403:1766-1778.
    >> Share

  22. ZHOU S, Zhou J
    New advances in amblyopia therapy: early patching is more effective than extended optical treatment.
    Lancet. 2024;403:1725-1727.
    >> Share

    April 2024
  23. WILENIUS M, Jernman J, Hietaharju A, Salonen T, et al
    Swollen eyelids caused by polyvinylpyrrolidone histiocytosis with intravenous methylphenidate.
    Lancet. 2024;403:1574-1575.
    >> Share

    March 2024
  24. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
    Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
    >> Share

  25. RAKOCZY EP
    The promise of long-term treatment for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
    >> Share

  26. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    >> Share

  27. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    >> Share

  28. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
    Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
    >> Share

  29. CHEW EY
    Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
    >> Share

  30. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    >> Share

    October 2023
  31. KHANANI AM, Patel SS, Staurenghi G, Tadayoni R, et al
    Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
    Lancet. 2023;402:1449-1458.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016